Navigation Links
Common Virus Enhances Cancer-Fighting Ability of Standard Chemotherapy Drugs

Can a common virus boost the cancer-killing abilities of existing cancer drugs? A preclinical study presented// at this year’s EORTC-NCI-AACR symposium on Molecular Targets and Cancer Therapeutics, in Prague, Czech Republic concluded that the answer is “yes.” These findings may lead to more effective treatment options for patients suffering from non-small cell lung cancer (NSCLC), a disease in which malignant (cancer) cells form in the tissues of the lung.

The research focused on work conducted by SAIC-Frederick, Inc., a prime contractor to the National Cancer Institute (NCI). The NCI tested the Respiratory Enteric Orphan virus, or reovirus, a non-disease causing virus in combination with a number of widely used chemotherapy drugs. In general, the combination of reovirus with cisplatin, gemcitabine, mitomycin or vinblastine was found to be more effective against NSCLC cell lines sensitive to anti-cancer drugs than each treatment used on its own. The study used REOLYSIN?, Oncolytics Biotech's proprietary formulation of the human reovirus, that has been demonstrated to replicate specifically in and kill tumor cells with activated Ras pathways (uncontrollable growth signals).

Of particular interest to the researchers, the combination of reovirus and paclitaxel, a common chemotherapy drug, was uniformly synergistic in all six cell lines examined, including in those with high-level resistance to paclitaxel or reovirus. The data suggest that the combination of reovirus and paclitaxel may help in promoting cell-death signaling, resulting in a more efficient and synergistic anti-cancer effect against these cell lines than using each agent on its own.

"Data from the NCI and other investigators examining various co-therapies with REOLYSIN is providing Oncolytics with the rationale for its planned combination clinical trial program," said Dr. Matt Coffey, the Chief Scientific Officer at Oncolytics. "This research suggests that REOLYSIN can be combined with many existing therapies that are currently broadly used in the treatment of cancer patients."

Currently, REOLYSIN is being used in Phase I and Phase I/II human clinical trials in the U.S. and the U.K. and the treatment has recently been approved for use in a Phase II trial in the U.K. for various advanced or metastatic cancers. The treatment appears to be well-tolerated by patients, and anti-tumor effects have been reported in all trials reported on to date. The Company plans to initiate human trials with REOLYSIN and various chemotherapies over the next year.

About 85% of all lung cancers are classified as the non-small cell type. Lung cancer is the leading cause of cancer death for both men and women. More people die of lung cancer than of colon, breast, and prostate cancers combined.

Source-Newswise
SM
'"/>




Related medicine news :

1. Common contraception
2. Common Cold Remedy May Treat SARS
3. Common Plant Triggers Asthma
4. Pain Common in People with MS
5. Common Cold Found to Fight Cancer
6. Bullying – a Common Problem Among Childre
7. Common Medication Errors in Children
8. A Common Cause Of Allergy That Goes Unnoticed
9. Genetic Breakthrough in Common Eye Problem
10. Common Cold Found to Fight Cancer Cells
11. Side Effects Of Some Common Drugs
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:6/25/2016)... ... June 25, 2016 , ... Austin residents seeking Mohs surgery ... of Mohs Surgery and to Dr. Russell Peckham for medical and surgical dermatology. , ... for skin cancer. The selective fellowship in Mohs Micrographic Surgery completed by Dr. Dorsey ...
(Date:6/25/2016)... Oklahoma City, Oklahoma (PRWEB) , ... June 25, ... ... to helping both athletes and non-athletes recover from injury. Recently, he has implemented ... for the Oklahoma City area —Johnson is one of the first doctors to ...
(Date:6/24/2016)... ... , ... June 19, 2016 is World Sickle Cell Observance Day. In an ... of holistic treatments, Serenity Recovery Center of Marne, Michigan, has issued a ... Cell Disease (SCD) is a disorder of the red blood cells, which can cause ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... Comfort Keepers® ... American Cancer Society and the Road To Recovery® program to drive cancer patients to ... and other adults to ensure the highest quality of life and ongoing independence. ...
(Date:6/24/2016)... Vegas, Nevada (PRWEB) , ... June 24, 2016 ... ... Las Vegas client, The Grove Investment Group (TGIG), has initiated cultivation and processing ... Grove, in Las Vegas and Pahrump, Nevada. , Puradigm is the manufacturer of ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... June 24, 2016  Arkis BioSciences, a leading ... and more durable cerebrospinal fluid treatments, today announced ... Series-A funding is led by Innova Memphis, followed ... other private investors.  Arkis, new financing will accelerate ... the market release of its in-licensed Endexo® technology. ...
(Date:6/23/2016)... Any dentist who has made an implant supported ... Many of them do not even offer this as a ... laboratory costs involved. And those who ARE able to offer ... high cost that the majority of today,s patients would not ... Zadeh , founder of Dental Evolutions Inc. and inventor of ...
(Date:6/23/2016)... INDIANAPOLIS , June 23, 2016 Roche ... received 510(k) clearance for its Elecsys BRAHMS PCT (procalcitonin) ... severe sepsis or septic shock. With this clearance, Roche ... provide a fully integrated solution for sepsis risk assessment ... associated with bacterial infection and PCT levels in blood ...
Breaking Medicine Technology: